Literature DB >> 9570376

Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer.

H Amaya1, N Tanigawa, C Lu, M Matsumura, T Shimomatsuya, T Horiuchi, R Muraoka.   

Abstract

To examine the association of vascular endothelial growth factor (VEGF) expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor (dThdPase/PD-ECGF) expression in human colorectal cancer, immunohistochemical studies were performed on 136 cases of resected colorectal cancer specimens using antibodies for VEGF, KDR, CD34 and dThdPase/PD-ECGF. Fifty-nine cases (43%) were evaluated as positive for VEGF staining and 71 cases (52%) were evaluated as positive for dThdPase/PD-ECGF staining. The expression of VEGF correlated significantly with vessel counts and the expression of dThdPase/PD-ECGF (P = 0.01 and 0.01, respectively). Cox proportional hazards model analysis showed that vessel counts and VEGF expression were significant and independent prognostic factors, but that KDR expression was not.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9570376     DOI: 10.1016/s0304-3835(97)00280-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  24 in total

1.  Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.

Authors:  Markku Miettinen; Maarit-Sarlomo Rikala; Janusz Rys; Jerzy Lasota; Zeng-Feng Wang
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

Review 2.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors.

Authors:  S Cascinu; F Graziano; V Catalano; M P Staccioli; S Barni; P Giordani; M C Rossi; A M Baldelli; P Muretto; A Valenti; G Catalano
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 4.  Inhibition of vascular endothelial growth factor in the treatment of solid tumors.

Authors:  Kim Margolin
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

5.  Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma.

Authors:  Xiao-Nan Sun; Wei-Guo Cao; Xin Wang; Qi Wang; Ben-Xing Gu; Qi-Chu Yang; Jian-Bin Hu; Hai Liu; Shu Zheng
Journal:  Tumour Biol       Date:  2011-08-19

6.  Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.

Authors:  Naoya Himuro; Yumiko Niiya; Takao Minakata; Yutaka Oshima; Daisuke Kataoka; Shigeru Yamamoto; Takashi Suzuki; Mitsutaka Kadokura
Journal:  Mol Clin Oncol       Date:  2018-09-25

Review 7.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

8.  Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast.

Authors:  S Shivakumar; B T Prabhakar; K Jayashree; M G R Rajan; Bharathi P Salimath
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-21       Impact factor: 4.553

9.  Expression of thymidine phosphorylase by macrophages in colorectal cancer tissues.

Authors:  Ji-Min Zhang; Takayuki Mizoi; Ken-Ichi Shiiba; Iwao Sasaki; Seiki Matsuno
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

10.  Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.

Authors:  J M Jürgensmeier; H-J Schmoll; J D Robertson; L Brooks; M Taboada; S R Morgan; D Wilson; P M Hoff
Journal:  Br J Cancer       Date:  2013-02-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.